Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ghofrani, Hossein Ardeschir (VerfasserIn) , Grünig, Ekkehard (VerfasserIn) , Jansa, Pavel (VerfasserIn) , Langleben, David (VerfasserIn) , Rosenkranz, Stephan (VerfasserIn) , Preston, Ioana R. (VerfasserIn) , Rahaghi, Franck (VerfasserIn) , Sood, Namita (VerfasserIn) , Busse, Dennis (VerfasserIn) , Meier, Christian (VerfasserIn) , Humbert, Marc (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 16, 2020
In: Pulmonary circulation
Year: 2020, Jahrgang: 10, Heft: 3, Pages: 2045894020942121
ISSN:2045-8940
DOI:10.1177/2045894020942121
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/2045894020942121
Volltext
Verfasserangaben:Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Pavel Jansa, David Langleben, Stephan Rosenkranz, Ioana R. Preston, Franck Rahaghi, Namita Sood, Dennis Busse, Christian Meier and Marc Humbert

MARC

LEADER 00000caa a2200000 c 4500
001 1738005275
003 DE-627
005 20220819013546.0
007 cr uuu---uuuuu
008 201105s2020 xx |||||o 00| ||eng c
024 7 |a 10.1177/2045894020942121  |2 doi 
035 |a (DE-627)1738005275 
035 |a (DE-599)KXP1738005275 
035 |a (OCoLC)1341375864 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ghofrani, Hossein Ardeschir  |d 1967-  |e VerfasserIn  |0 (DE-588)120657686  |0 (DE-627)08081154X  |0 (DE-576)292326254  |4 aut 
245 1 0 |a Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)  |c Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Pavel Jansa, David Langleben, Stephan Rosenkranz, Ioana R. Preston, Franck Rahaghi, Namita Sood, Dennis Busse, Christian Meier and Marc Humbert 
264 1 |c July 16, 2020 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 05.11.2020 
520 |a Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present findings from patients who were receiving combined riociguat plus endothelin receptor antagonists or non-intravenous prostanoids in the randomized, placebo-controlled PATENT-1 study and its open-label extension (PATENT-2). Moreover, we include new data from patients receiving early sequential combination therapy (three to six months of endothelin receptor antagonist treatment) or long-term background endothelin receptor antagonist therapy (>6 months). Patients were randomized to riociguat 2.5 mg-maximum (N = 131 pretreated patients) and placebo (N = 60 pretreated patients). Riociguat improved 6-min walking distance (PATENT-1 primary endpoint), functional capacity, and hemodynamics after 12 weeks in pretreated patients. The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients. In the early sequential combination and long-term background endothelin receptor antagonist groups, the placebo-corrected changes in 6-min walking distance were +65 m (95% CI: 17 to 113 m) and +13 m (95% CI: -8 to 33 m), respectively. In conclusion, these data suggest that early sequential combination of an endothelin receptor antagonist plus riociguat is a feasible treatment option. Both early sequential therapy and long-term background endothelin receptor antagonist plus riociguat were well tolerated in the PATENT studies. 
700 1 |a Grünig, Ekkehard  |e VerfasserIn  |0 (DE-588)112535801  |0 (DE-627)618892605  |0 (DE-576)31856694X  |4 aut 
700 1 |a Jansa, Pavel  |e VerfasserIn  |4 aut 
700 1 |a Langleben, David  |e VerfasserIn  |4 aut 
700 1 |a Rosenkranz, Stephan  |d 1966-  |e VerfasserIn  |0 (DE-588)115007814  |0 (DE-627)506349608  |0 (DE-576)289815894  |4 aut 
700 1 |a Preston, Ioana R.  |e VerfasserIn  |4 aut 
700 1 |a Rahaghi, Franck  |e VerfasserIn  |4 aut 
700 1 |a Sood, Namita  |e VerfasserIn  |4 aut 
700 1 |a Busse, Dennis  |e VerfasserIn  |4 aut 
700 1 |a Meier, Christian  |e VerfasserIn  |4 aut 
700 1 |a Humbert, Marc  |d 1963-  |e VerfasserIn  |0 (DE-588)138789223  |0 (DE-627)703106708  |0 (DE-576)309065089  |4 aut 
773 0 8 |i Enthalten in  |t Pulmonary circulation  |d Hoboken, NJ : Wiley, 2011  |g 10(2020,3) Artikel-Nummer 2045894020942121, 10 Seiten  |h Online-Ressource  |w (DE-627)672806649  |w (DE-600)2638089-4  |w (DE-576)353570435  |x 2045-8940  |7 nnas  |a Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies) 
773 1 8 |g volume:10  |g year:2020  |g number:3  |g pages:2045894020942121  |g extent:10  |a Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies) 
856 4 0 |u https://doi.org/10.1177/2045894020942121  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20201105 
993 |a Article 
994 |a 2020 
998 |g 112535801  |a Grünig, Ekkehard  |m 112535801:Grünig, Ekkehard  |d 910000  |d 950000  |d 950900  |e 910000PG112535801  |e 950000PG112535801  |e 950900PG112535801  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 2 
999 |a KXP-PPN1738005275  |e 3792728869 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 05.11.2020"],"recId":"1738005275","name":{"displayForm":["Hossein-Ardeschir Ghofrani, Ekkehard Grünig, Pavel Jansa, David Langleben, Stephan Rosenkranz, Ioana R. Preston, Franck Rahaghi, Namita Sood, Dennis Busse, Christian Meier and Marc Humbert"]},"id":{"eki":["1738005275"],"doi":["10.1177/2045894020942121"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"July 16, 2020"}],"relHost":[{"origin":[{"dateIssuedKey":"2011","publisher":"Wiley ; Medknow Publ. ; Univ. of Chicago Press ; Sage Publications","dateIssuedDisp":"2011-","publisherPlace":"Hoboken, NJ ; Mumbai ; Chicago, Ill. ; Thousand Oaks, CA"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"eki":["672806649"],"zdb":["2638089-4"],"issn":["2045-8940"]},"language":["eng"],"part":{"text":"10(2020,3) Artikel-Nummer 2045894020942121, 10 Seiten","pages":"2045894020942121","volume":"10","issue":"3","extent":"10","year":"2020"},"title":[{"title_sort":"Pulmonary circulation","title":"Pulmonary circulation","subtitle":"official journal of the Pulmonary Vascular Research Institute"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)Pulmonary circulation","pubHistory":["1.2011 -"],"note":["Gesehen am 26.07.2024"],"recId":"672806649"}],"person":[{"role":"aut","given":"Hossein Ardeschir","display":"Ghofrani, Hossein Ardeschir","family":"Ghofrani"},{"role":"aut","given":"Ekkehard","family":"Grünig","display":"Grünig, Ekkehard"},{"display":"Jansa, Pavel","family":"Jansa","given":"Pavel","role":"aut"},{"role":"aut","given":"David","display":"Langleben, David","family":"Langleben"},{"display":"Rosenkranz, Stephan","family":"Rosenkranz","given":"Stephan","role":"aut"},{"given":"Ioana R.","family":"Preston","display":"Preston, Ioana R.","role":"aut"},{"given":"Franck","family":"Rahaghi","display":"Rahaghi, Franck","role":"aut"},{"given":"Namita","display":"Sood, Namita","family":"Sood","role":"aut"},{"role":"aut","family":"Busse","display":"Busse, Dennis","given":"Dennis"},{"display":"Meier, Christian","family":"Meier","given":"Christian","role":"aut"},{"role":"aut","display":"Humbert, Marc","family":"Humbert","given":"Marc"}],"title":[{"title":"Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)","title_sort":"Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)"}],"physDesc":[{"extent":"10 S."}]} 
SRT |a GHOFRANIHOEFFICACYAN1620